Clinical-stage biopharmaceutical developer of cell-derived, cell-free secretome therapies for patients with fibrotic diseases, aiming to enable tissue regeneration and disease remission to improve quality of life. Lead product RC-0315 is a secretome-based candidate currently in a Phase Ib trial for idiopathic pulmonary fibrosis.